Drug Interactions between Antimicrobial and. Immunosuppressive Agents in Solid Organ Transplant Recipients

被引:16
作者
Bhagat, Vikas [1 ]
Pandit, Rahul A. [2 ]
Ambapurkar, Shwetha [3 ]
Sengar, Manju [4 ]
Kulkarni, Atul P. [5 ]
机构
[1] Aster Hosp, Dept Crit Care Med, Dubai, U Arab Emirates
[2] Fortis Hosp, Mumbai, Maharashtra, India
[3] Fortis Hosp, Dept Pharmacol, Mumbai, Maharashtra, India
[4] Homi Bhabha Natl Inst, Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[5] Homi Bhabha Natl Inst, Tata Mem Hosp, Dept Anesthesia Crit Care & Pain, Div Crit Care Med, Mumbai, Maharashtra, India
关键词
Antimicrobials; Calcineurin inhibitors; Corticosteroids; Drug-drug interaction; Immunosuppressants; Intravenous immunoglobulin; Monoclonal antibodies; mTOR inhibitors; Solid organ transplant; PHARMACOKINETIC INTERACTION; INTRAVENOUS AZITHROMYCIN; ORAL BIOAVAILABILITY; AZOLE ANTIFUNGALS; TACROLIMUS LEVELS; P-GLYCOPROTEIN; INFECTED LIVER; CYCLOSPORINE-A; IN-VITRO; THERAPY;
D O I
10.5005/jp-journals-10071-23439
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The number of allogenic solid organ and bone marrow transplants is increasing all over the world. To prevent transplant rejection and treat acute rejection of transplant, immunosuppressant drugs are used.The outcomes of solid organ transplants have dramatically improved over last 30 years, due to availability of multiple immunosuppressive agents, with varied mechanisms of action. The use of intense immunosuppression makes the individual having undergone solid organ transplant at the risk of several serious infections, which may prove fatal. To prevent and treat these infections (when they occur), patients are often given antimicrobial prophylaxis and therapy. The use of antimicrobials can interfere with the metabolism of the immunosuppressants, and may put the patient at risk of developing severe adverse effects due to unwanted increase or decrease in the serum levels of immunosuppressive agents. Knowledge of these interactions is essential for successful management of solid organ transplant patients. We therefore decided to review the literature and present the interactions that commonly occur between these two life-saving groups of drugs.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 69 条
[1]  
[Anonymous], 2013, AFINITOR EV TABL 2 5
[2]   Classifying drug interactions [J].
Aronson, JK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) :343-344
[3]  
Astellas Pharma US Inc, 2011, MYC MIC INJ INTR US
[4]   New frontiers in immunosuppression [J].
Benvenuto, Luke J. ;
Anderson, Michaela R. ;
Arcasoy, Selim M. .
JOURNAL OF THORACIC DISEASE, 2018, 10 (05) :3141-3155
[5]   Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome p450 inhibitors: A case report [J].
Bhaloo, S ;
Prasad, GVR .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) :2449-2451
[6]   Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient [J].
Billaud, E. M. ;
Antoine, C. ;
Berge, M. ;
Abboud, I. ;
Lefeuvre, S. ;
Benammar, M. ;
Glotz, D. .
CLINICAL DRUG INVESTIGATION, 2009, 29 (07) :481-486
[7]   The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation [J].
Borrows, Richard ;
Chusney, Gary ;
Loucaidou, Marina ;
James, Anthony ;
Van Tromp, Jen ;
Cairns, Tom ;
Griffith, Megan ;
Hakim, Nadey ;
McLean, Adam ;
Palmer, Andrew ;
Papalois, Vassilios ;
Taube, David .
THERAPEUTIC DRUG MONITORING, 2007, 29 (01) :122-126
[8]   Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents [J].
Bruggemann, Roger J. M. ;
Alffenaar, Jan-Willem C. ;
Blijlevens, Nicole M. A. ;
Billaud, Eliane M. ;
Kosterink, Jos G. W. ;
Verweij, Paul E. ;
Burger, David M. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (10) :1441-1458
[9]   Absence of Pharmacokinetic Interference of Moxifloxacin on Cyclosporine and Tacrolimus in Kidney Transplant Recipients [J].
Capone, Domenico ;
Tarantino, Giovanni ;
Polichetti, Giuliano ;
Kadilli, Irket ;
Sabbatini, Massimo ;
Basile, Vincenzo ;
Carrano, Rosa ;
Nappi, Riccardo ;
Federico, Stefano .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (05) :576-580
[10]   Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy [J].
Carver, PL ;
Whang, E ;
VandenBussche, HL ;
Kauffman, CA ;
Malani, PN .
PHARMACOTHERAPY, 2003, 23 (02) :159-164